Table 3.
RR, median PFS, and TTP or TTF of eribulin and other chemotherapeutic agents given as first-line for locally advanced and metastatic breast cancer.
| REGIMEN | HER2-TARGETED TREATMENT | RR (95% CONFIDENCE INTERVAL) | MEDIAN PFS OR TTP OR TTF | REF. |
|---|---|---|---|---|
| Weekly paclitaxel | Yes | 42% (37–47%) | 9.0 mo (TTP) | 18 |
| Docetaxel, Q3W | No | 68% | 7.2 mo (TTP) | 24 |
| Weekly gemcitabine | No | 37.1% (21.5–55.1%) | 5.1 mo (95% CI, 3.5–8.8 mo) (TTP) | 22 |
| Weekly vinorelbine | No | 50% (CR 2%) | 5.0 mo (TTF) | 25 |
| Ixabepilone, Q3W | All HER2-negative | 47% (29–65%) | 9.0 mo (4–14 mo) (PFS) | 23 |
| Weekly eribulin | Yes | 71.2% (56.9–82.9%) | 11.6 mo (9.1–11.3 mo) (PFS) | 17 |
| Weekly eribulin (29% of pts received prior anthracycline and/or taxane) | All HER2-negative | 54.3% (CR 5.7%) | 5.8 mo (PFS) 5.4 mo (TTF) | 15 |
| Weekly eribulin (59% of pts received prior anthracycline and/or taxane) | All HER2-negative | 29% (17.3–42.2%) | 6.8 mo (4.4–7.6 mo) (PFS) | 16 |
Abbreviations: mo, months; PFS, progression-free survival; RR, response rate; TTF, time-to-treatment failure; TTP, time to progression.